Comgenica selected Institute of Immunology and Genetics in Kaiserslautern to accelerate its whole exome sequencing

/in

Link to Full Article Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a new contract with the Institute of Immunology and Genetics (‘IIG’ or the ‘Institute’) a leading molecular genetic laboratory in Kaiserslautern, Germany, equipped with state-of-the-art equipment and comprehensive human genetic and bioinformatic expertise.   From analysis of established gene variants, […]

Read more

ARECOR RECEIVES £2.8 MILLION GRANT AWARD FROM INNOVATE UK

/in

Link to Full Article Coveted award for Phase II clinical development of lead product, AT247, its next generation ultra-rapid acting Insulin Cambridge, UK., 31 st Mar 2021: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that it has been awarded a £2.8 million grant from […]

Read more

Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel

/in

Link to Full Article Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001) Excellent safety profile. No treatment related adverse events Brighton, United Kingdom – 29th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]

Read more

Multi-year study will use Congenica’s platform for rapid and accurate genomic analysis

/in

Link to Full Article Sioux Falls, South Dakota, United States and Cambridge, UK – 25 March 2021  Sanford Health (‘Sanford’), a leading US-based healthcare delivery system provider and Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples’ lives, today announce a genomics partnership focused on providing answers for patients […]

Read more

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update

/in

Link to Full Article MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the fourth quarter and full year 2020 and provided a corporate and clinical update. Fourth Quarter […]

Read more

Destiny Pharma Notice of Full Year Results and Clinical Trial Update

/in

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Clinical Trial Update Brighton, United Kingdom – 16th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for […]

Read more

Destiny Pharma Announces Agreement with NIAID

/in

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection Brighton, United Kingdom, 15 March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces […]

Read more

Congenica signs distribution agreement with AmpliTech in France

/in

Link to Full Article AmpliTech to distribute Congenica’s world-leading NGS data analysis and clinical decision support software in France Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces a new distribution agreement with AmpliTech, a leading French distribution company dedicated to the commercialisation of innovative products, software, and instruments for in […]

Read more

CalciMedica Announces $21 Million Series D Financing

/in

Link to Full Article Round led Quark Venture LP and Global Health Sciences (GHS) Fund Funds to support advancement of anti-inflammatory therapy, AuxoraTM, currently being evaluated in severe and critical COVID-19 pneumonia and acute pancreatitis with SIRS Zafi Avnur, Ph.D., chief scientific officer and partner at Quark Venture, joins Board of Director LA JOLLA, […]

Read more

Destiny Pharma CSO Joins UKRI COVID-19 Taskforce

/in

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Chief Scientific Officer Dr Bill Love Joins UKRI COVID-19 Research and Innovation Taskforce Brighton, United Kingdom – 10th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can […]

Read more